Complete financial analysis of SIGA Technologies, Inc. (SIGA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SIGA Technologies, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Tower Resources Ltd. (TWRFF) Income Statement Analysis – Financial Results
- Sun TV Network Limited (SUNTV.NS) Income Statement Analysis – Financial Results
- Fabryki Mebli FORTE S.A. (FTE.WA) Income Statement Analysis – Financial Results
- Shanghai Jahwa United Co., Ltd. (600315.SS) Income Statement Analysis – Financial Results
- Urban One, Inc. (UONE) Income Statement Analysis – Financial Results
SIGA Technologies, Inc. (SIGA)
About SIGA Technologies, Inc.
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 139.92M | 110.78M | 133.67M | 124.96M | 26.74M | 477.05M | 12.27M | 14.99M | 8.18M | 3.14M | 5.52M | 8.97M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 483.12K | 500.00K | 500.00K | 700.00K | 100.00K |
| Cost of Revenue | 17.83M | 32.96M | 26.54M | 25.74M | 15.09M | 108.29M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -945.40K | -400.00K | -200.00K | 0.00 | 0.00 |
| Gross Profit | 122.09M | 77.82M | 107.13M | 99.22M | 11.66M | 368.77M | -4.41M | -4.72M | -4.95M | -7.69M | -8.34M | -9.24M | 12.73M | 19.22M | 13.81M | 8.07M | 6.70M | 7.26M | 8.48M | 1.84M | 731.74K | 344.45K | 1.16M | 1.43M | 900.00K | 700.00K | 700.00K | 100.00K |
| Gross Profit Ratio | 87.26% | 70.25% | 80.14% | 79.40% | 43.59% | 77.30% | -35.95% | -31.51% | -60.60% | -244.93% | -151.06% | -103.02% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 295.69% | 180.00% | 140.00% | 100.00% | 100.00% |
| Research & Development | 16.43M | 24.11M | 9.94M | 10.94M | 13.30M | 13.02M | 16.68M | 19.71M | 13.13M | 10.83M | 13.86M | 18.21M | 18.37M | 22.66M | 17.42M | 11.61M | 9.94M | 9.15M | 8.30M | 4.17M | 2.94M | 1.77M | 1.73M | 2.61M | 1.70M | 2.90M | 900.00K | 700.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.88M | 12.30M | 13.71M | 24.99M | 200.99M | 1.42M | 1.88M | 25.74M | 1.15M | 734.17K | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.41M | -188.47M | 11.82M | 9.53M | 0.00 | 8.13M | 7.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.04M | 35.12M | 17.32M | 14.00M | 13.25M | 12.88M | 12.30M | 13.71M | 10.58M | 12.52M | 13.24M | 11.41M | 25.74M | 9.28M | 8.27M | 5.19M | 4.22M | 4.92M | 2.71M | 4.44M | 2.95M | 1.94M | 2.57M | 4.96M | 2.30M | 2.80M | 2.00M | 800.00K |
| Other Expenses | 0.00 | -24.11M | 710.15K | 719.14K | 726.11K | 78.94M | 16.79K | -1.66M | 42.20K | 1.07K | 1.50K | 522.00 | 0.00 | 0.00 | 4.35B | 0.00 | 0.00 | 0.00 | 0.00 | 2.12M | 136.75K | 0.00 | 117.26K | 945.40K | 400.00K | 200.00K | 100.00K | 0.00 |
| Operating Expenses | 22.04M | 35.12M | 18.03M | 14.72M | 13.98M | 13.67M | 13.21M | 14.62M | 11.59M | 13.51M | 14.67M | 13.29M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 8.51M | 4.40M | 5.90M | 3.00M | 1.50M |
| Cost & Expenses | 56.30M | 68.08M | 44.58M | 40.46M | 29.06M | 121.95M | 29.89M | 34.33M | 24.72M | 24.34M | 28.52M | 31.51M | 44.11M | 31.94M | 25.69M | 16.80M | 14.16M | 14.07M | 11.01M | 10.72M | 6.03M | 3.71M | 4.42M | 7.57M | 4.00M | 5.70M | 3.00M | 1.50M |
| Interest Income | 4.16M | 0.00 | 101.17K | 2.48M | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.26K | 34.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 3.02M | 15.77M | 15.48M | 14.76M | 14.06M | 266.73K | 455.81K | 1.21M | 172.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 192.68K | 550.46K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 538.29K | 517.64K | 522.37K | 529.81K | 527.00K | 69.63K | 132.19K | 174.28K | 247.36K | 351.56K | 463.14K | 419.36K | 568.29K | 625.34K | 475.09K | 459.88K | 1.25M | 1.56M | 1.33M | 1.05M | 739.56K | 317.03K | 556.86K | 945.40K | 400.00K | 200.00K | 100.00K | 900.00K |
| EBITDA | 84.16M | 43.22M | 89.62M | 85.03M | 1.03M | 355.17M | -23.44M | -25.45M | -38.48M | -211.13M | -23.13M | -21.78M | -21.87M | -27.57M | -11.40M | -8.28M | -6.21M | -5.25M | -1.20M | -8.32M | -4.56M | -3.05M | -2.70M | -6.14M | -3.08M | -5.00M | -1.80M | -500.00K |
| EBITDA Ratio | 60.15% | 39.48% | 67.12% | 68.47% | 3.84% | 91.00% | -142.43% | -139.01% | -198.83% | -664.03% | -408.36% | -246.53% | -312.41% | 17.57% | -41.01% | -104.33% | -120.00% | -29.85% | -17.10% | -283.50% | -603.84% | -884.91% | -199.45% | -1,238.31% | -620.00% | -740.00% | -314.29% | -500.00% |
| Operating Income | 83.62M | 42.70M | 89.09M | 84.50M | 500.09K | 355.10M | -18.85M | -31.01M | -30.95M | -209.67M | -23.52M | -22.54M | -31.38M | -12.72M | -11.88M | -8.74M | -7.46M | -6.81M | -2.53M | -9.45M | -5.29M | -3.37M | -3.26M | -7.08M | -3.50M | -5.20M | -2.30M | -1.40M |
| Operating Income Ratio | 59.76% | 38.55% | 66.65% | 67.62% | 1.87% | 74.44% | -153.63% | -206.94% | -378.59% | -6,677.64% | -426.07% | -251.21% | -246.60% | -66.21% | -86.01% | -108.32% | -111.41% | -93.84% | -29.87% | -513.72% | -723.60% | -976.95% | -281.31% | -1,466.21% | -700.00% | -1,040.00% | -328.57% | -1,400.00% |
| Total Other Income/Expenses | 4.16M | 1.43M | 218.94K | -10.99M | -7.86M | 56.54M | -19.48M | -8.67M | -8.04M | -2.27M | -1.28M | 632.05K | 8.94M | -37.45M | -5.74M | 137.53K | 1.82M | -3.09M | 244.79K | 74.97K | -136.75K | 0.00 | -392.37K | -155.59K | 0.00 | -1.30M | 0.00 | -900.00K |
| Income Before Tax | 87.78M | 44.13M | 89.31M | 73.51M | -10.18M | 411.64M | -38.33M | -39.68M | -38.99M | -211.93M | -24.80M | -22.37M | -22.44M | -19.40M | -17.62B | -8.60M | -5.64M | -9.90M | -2.29M | -12.06M | -5.43M | 0.00 | -3.65M | -7.24M | 0.00 | -6.50M | 0.00 | -2.30M |
| Income Before Tax Ratio | 62.73% | 39.84% | 66.81% | 58.83% | -38.06% | 86.29% | -312.41% | -264.78% | -476.88% | -6,749.87% | -449.26% | -249.39% | -176.31% | -100.96% | -127,556.62% | -106.62% | -84.17% | -136.39% | -26.99% | -655.72% | -742.29% | 0.00% | -315.15% | -1,498.41% | 0.00% | -1,300.00% | 0.00% | -2,300.00% |
| Income Tax Expense | 19.71M | 10.23M | 19.86M | 17.17M | -2.94M | -10.17M | -2.09M | 13.88K | 461.98K | 53.53M | -7.62M | -7.84M | -36.03M | 15.47M | 5.74M | -137.53K | -1.82M | 3.09M | -244.79K | 493.36K | -18.26K | -34.06K | 467.79K | 706.06K | 100.00K | 1.40M | -100.00K | 0.00 |
| Net Income | 68.07M | 33.90M | 69.45M | 56.34M | -7.24M | 421.81M | -36.24M | -39.70M | -39.45M | -265.46M | -17.18M | -14.53M | 13.59M | -28.20M | -17.62M | -8.60M | -5.64M | -9.90M | -2.29M | -9.37M | -5.28M | -3.33M | -3.73M | -7.79M | -3.60M | -6.60M | -2.20M | -2.30M |
| Net Income Ratio | 48.65% | 30.61% | 51.96% | 45.09% | -27.08% | 88.42% | -295.34% | -264.87% | -482.53% | -8,454.68% | -311.22% | -161.95% | 106.82% | -146.73% | -127.56% | -106.62% | -84.17% | -136.39% | -26.99% | -509.65% | -721.11% | -967.06% | -321.66% | -1,612.35% | -720.00% | -1,320.00% | -314.29% | -2,300.00% |
| EPS | 0.95 | 0.46 | 0.92 | 0.71 | -0.09 | 5.28 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.57 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| EPS Diluted | 0.95 | 0.46 | 0.91 | 0.71 | -0.09 | 5.10 | -0.46 | -0.69 | -0.73 | -4.97 | -0.33 | -0.28 | 0.09 | -0.62 | -0.47 | -0.25 | -0.17 | -0.35 | -0.09 | -0.40 | -0.34 | -0.32 | -0.44 | -1.08 | -0.55 | -1.01 | -0.57 | -0.75 |
| Weighted Avg Shares Out | 71.36M | 72.93M | 75.32M | 79.26M | 81.03M | 79.92M | 78.77M | 57.19M | 53.78M | 53.41M | 52.05M | 51.64M | 50.93M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.58M | 6.54M | 3.89M | 3.07M |
| Weighted Avg Shares Out (Dil) | 71.68M | 73.55M | 76.40M | 79.44M | 82.18M | 82.71M | 78.87M | 57.19M | 53.78M | 53.42M | 52.37M | 51.64M | 54.06M | 45.15M | 37.46M | 34.73M | 33.33M | 28.20M | 24.82M | 23.72M | 15.72M | 10.45M | 8.50M | 7.20M | 6.59M | 6.55M | 3.89M | 3.07M |
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SIGA Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / October 9, 2024 / Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®,...
SIGA ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by SIGA Technologies, Inc.
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
Siga Technologies to supply mpox therapy in Morocco
Drugmaker Siga Technologies said on Tuesday it would supply its therapy for mpox in Morocco, in response to a request from the country's health ministry for protection against any potential outbreak of the disease.
SIGA Announces Agreement to Supply TPOXX® in Morocco
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company and leader in infectious diseases, today announced that it entered into an agreement to supply TPOXX (tecovirimat) in Morocco. The contract was...
ATTENTION SIGA SHAREHOLDERS: Investors who Lost Money on SIGA Technologies, Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
SIGA ALERT: Bragar Eagel & Squire, P.C. is Investigating SIGA Technologies, Inc. on Behalf of SIGA Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against SIGA Technologies, Inc. (“SIGA” or the “Company”) (NASDAQ: SIGA) on behalf of SIGA stockholders. Our...
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.
Lost Money on SIGA Technologies, Inc. (SIGA)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of SIGA Technologies, Inc. ("SIGA Technologies, Inc.") (NASDAQ:SIGA) concerning possible violations of federal securities laws. On September 25, 2024,...
Siga Technologies Inc. (SIGA) Ascends But Remains Behind Market: Some Facts to Note
Siga Technologies Inc. (SIGA) closed at $6.99 in the latest trading session, marking a +0.36% move from the prior day.
SIGA Technologies (SIGA) Shares Tumble After Mpox Therapy Fails, Chief Medical Officer Terminated - Hagens Berman
SAN FRANCISCO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Biopharmaceutical company SIGA Technologies is under intense scrutiny over its prior disclosures regarding the potential expansion of its lead product, TPOXX®, to treat Mpox.
Source: https://incomestatements.info
Category: Stock Reports